<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34864363</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis.</ArticleTitle><Pagination><StartPage>103732</StartPage><MedlinePgn>103732</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">103732</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2021.103732</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(21)00526-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The survival time of amyotrophic lateral sclerosis (ALS) is greatly variable and protective or risk effects of the potential survival predictors are controversial. Thus, we aim to undertake a comprehensive meta-analysis of studies investigating non-genetic prognostic and survival factors in patients with ALS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A search of relevant literature from PubMed, Embase, Cochrane library and other citations from 1<sup>st</sup> January 1966 to 1<sup>st</sup> December 020 was conducted. Random-effects models were conducted to pool the multivariable or adjusted hazard ratios (HR) by Stata MP 16.0. PROSPERO registration number: CRD42021256923.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">A total of 5717 reports were identified, with 115 studies meeting pre-designed inclusion criteria involving 55,169 ALS patients. Five dimensions, including demographic, environmental or lifestyle, clinical manifestations, biochemical index, therapeutic factors or comorbidities were investigated. Twenty-five prediction factors, including twenty non-intervenable and five intervenable factors, were associated with ALS survival. Among them, NFL (HR:3.70, 6.80, in serum and CSF, respectively), FTD (HR:2.98), ALSFRS-R change (HR:2.37), respiratory subtype (HR:2.20), executive dysfunction (HR:2.10) and age of onset (HR:1.03) were superior predictors for poor prognosis, but pLMN or pUMN (HR:0.32), baseline ALSFRS-R score (HR:0.95), duration (HR:0.96), diagnostic delay (HR:0.97) were superior predictors for a good prognosis. Our results did not support the involvement of gender, education level, diabetes, hypertension, NIV, gastrostomy, and statins in ALS survival.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our study provided a comprehensive and quantitative index for assessing the prognosis for ALS patients, and the identified non-intervenable or intervenable factors will facilitate the development of treatment strategies for ALS.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">This study was supported by the National Natural Science Fund of China (Grant No. 81971188), the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Grant No. 2019HXFH046), and the Science and Technology Bureau Fund of Sichuan Province (No. 2019YFS0216).</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Wei-Ming</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, Rare disease center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yang-Fan</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, Rare disease center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, Rare disease center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Qing-Qing</ForeName><Initials>QQ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, Rare disease center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Tian-Mi</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, Rare disease center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Hui-Fang</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, Rare disease center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: hfshang2002@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong-Ping</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, Rare disease center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: yongping.chen@wchscu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Hazard ratios</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword><Keyword MajorTopicYN="N">Predictors</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>5</Day><Hour>21</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34864363</ArticleId><ArticleId IdType="pmc">PMC8646173</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2021.103732</ArticleId><ArticleId IdType="pii">S2352-3964(21)00526-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B., Gendron T.F., Staff N.P. Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clin Proc. 2018;93:1617&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder D.W., Kurland L.T., Offord K.P., Beard C.M. Familial adult motor neuron disease: amyotrophic lateral sclerosis. Neurology. 1986;36:511&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">3960325</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., Horton D.K., Kasarskis E.J., Tessaro E., Eisenberg M.S., Laird S., Iskander J. CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions. MMWR Morb Mortal Wkly Rep. 2017;66:1379&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5751576</ArticleId><ArticleId IdType="pubmed">29267263</ArticleId></ArticleIdList></Reference><Reference><Citation>Testa D., Lovati R., Ferrarini M., Salmoiraghi F., Filippini G. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:208&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">15799548</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Logroscino G., Hardiman O., Swingler R., Mitchell D., Beghi E., Traynor BG. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10:310&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackrivo J., Hansen-Flaschen J., Wileyto E.P., Schwab R.J., Elman L., Kawut S.M. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis. Eur Respir J. 2019;53</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6684229</ArticleId><ArticleId IdType="pubmed">30728207</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M., Bede P., Montuschi A., Pender N., Chio A., Hardiman O. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J Neurol. 2015;262:1447&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469087</ArticleId><ArticleId IdType="pubmed">25860344</ArticleId></ArticleIdList></Reference><Reference><Citation>Grollemund V., Chat G.L., Secchi-Buhour M.S., Delbot F., Pradat-Peyre J.F., Bede P., Pradat PF. Development and validation of a 1-year survival prognosis estimation model for Amyotrophic Lateral Sclerosis using manifold learning algorithm UMAP. Sci Rep. 2020;10:13378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7414917</ArticleId><ArticleId IdType="pubmed">32770027</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp L.J., Appel V., Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118:707&#x2013;719. (Pt 3)</Citation><ArticleIdList><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H.J., Debray T.P.A., Visser A.E. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q.Q., Chen Y., Chen X. Prognostic Nomogram Associated with Longer Survival in Amyotrophic Lateral Sclerosis Patients. Aging Dis. 2018;9:965&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6284758</ArticleId><ArticleId IdType="pubmed">30574410</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg LH. Amyotrophic lateral sclerosis. The Lancet. 2017;390:2084&#x2013;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulisz D. Amyotrophic lateral sclerosis: disease state overview. Am J Manag Care. 2018;24:S320&#x2013;S3S6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207670</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Moglia C., Canosa A. ALS phenotype is influenced by age, sex, and genetics: A population-based study. Neurology. 2020;94:e802&#x2013;ee10.</Citation><ArticleIdList><ArticleId IdType="pubmed">31907290</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.P., Yu S.H., Wei Q.Q. Role of genetics in amyotrophic lateral sclerosis: a large cohort study in Chinese mainland population. J Med Genet. 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">34544842</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott CJ. Clinical trials in amyotrophic lateral sclerosis. Curr Opin Neurol. 2019;32:758&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">31335338</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup D.F., Berlin J.A., Morton S.C. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Mitchell J.D., Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012;2012</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz M.E., van den Berg L.H., Shefner J.M. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P., Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">7786990</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M., Smith G.D., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj-Brit Med J. 1997;315:629&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren N., Scott K.M., Tsuda M. Evidence of an environmental effect on survival in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:528&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">24862874</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P., Levy G., Thompson J.L. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64:38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642901</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf J., Safer A., W&#xf6;hrle J.C., Palm F., Nix W.A., Maschke M., Grau AJ. Factors Predicting Survival in ALS Patients&#x2013;Data from a Population-Based Registry in Rhineland-Palatinate, Germany. Neuroepidemiology. 2015;44:149&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">25895515</ArticleId></ArticleIdList></Reference><Reference><Citation>Forbes R.B., Colvile S., Cran G.W., Swingler RJ. Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone disease. Journal of Neurology, Neurosurgery and Psychiatry. 2004;75:1753&#x2013;1755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738850</ArticleId><ArticleId IdType="pubmed">15548498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.Y., Chen W., Xu W. Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2019;72:1353&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pubmed">31744001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.H., Macdonald-Wallis C., Gray E. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nature Reviews Neurology. 2014;10:661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Pender N., Pinto-Grau M., Hardiman O. Cognitive and behavioural impairment in amyotrophic lateral sclerosis. Curr Opin Neurol. 2020;33:649&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">32833751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P., Levy G., Thompson J.L.P. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64:38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642901</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard S.R., Wuu J., Cardoso M. Urinary p75ECD: A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88:1137&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgrave L.M., Ma M., Best J.R., DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Alzheimers Dement (Amst) 2019;11:730&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939029</ArticleId><ArticleId IdType="pubmed">31909174</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S., Vacchiano V., Zenesini C. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. Journal of Neurology. 2020;267:1699&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pubmed">32100123</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F., Zhu Y., Hsiao-Nakamoto J. Longitudinal biomarkers in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology. 2020;7:1103&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber S., Spotorno N., Schreiber F. Significance of CSF NfL and tau in ALS. Journal of Neurology. 2018;265:2633&#x2013;2645.</Citation><ArticleIdList><ArticleId IdType="pubmed">30187162</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B., De Schaepdryver M., Goossens J. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol Appl Neurobiol. 2019;45:291&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">29908069</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M., Lunetta C., Tarlarini C., Mosca L., Chio A., Van Damme P., Poesen K. Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020;91:436&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">32029541</ArticleId></ArticleIdList></Reference><Reference><Citation>Thouvenot E., Demattei C., Lehmann S. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. European Journal of Neurology. 2020;27:251&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437330</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K.B., Glass J.D., Crook J.E. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in Amyotrophic Lateral Sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 2013;84:467&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">23117489</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M., Goossens J., Jeromin A. Phosphorylated neurofilament heavy chains (pNfH) in blood as an early diagnostic and prognostic biomarker in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2018;19:45&#x2013;46.</Citation></Reference><Reference><Citation>Falzone Y.M., Domi T., Agosta F. Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease. Journal of Neurology. 2020;267:2272&#x2013;2280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166001</ArticleId><ArticleId IdType="pubmed">32306171</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron T.F., Daughrity L.M., Heckman M.G. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Ann Neurol. 2017;82:139&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5676468</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId></ArticleIdList></Reference><Reference><Citation>Kansal K., Mareddy M., Sloane K.L., Minc A.A., Rabins P.V., McGready J.B., Onyike CU. Survival in Frontotemporal Dementia Phenotypes: A Meta-Analysis. Dementia and Geriatric Cognitive Disorders. 2016;41:109&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">26854827</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney R.K., Murphy J., Forshew D. The effects of executive and behavioral dysfunction on the course of ALS. Neurology. 2005;65:1774&#x2013;1777.</Citation><ArticleIdList><ArticleId IdType="pubmed">16344521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F., Fujimura C., Ishida S. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J., Menon P., Byth K., Morrison S., Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2016;87:628&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon P.H., Cheung YK. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;67:1314&#x2013;1315. author reply -5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030785</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Calvo A., Moglia C., Mazzini L., Mora G., group Ps. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82:740&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoesmith C.L., Findlater K., Rowe A., Strong MJ. Prognosis of amyotrophic lateral sclerosis with respiratory onset. Journal of Neurology, Neurosurgery and Psychiatry. 2007;78:629&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077959</ArticleId><ArticleId IdType="pubmed">17088331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M.D., Little J., Gomes J., Cashman N.R., Krewski D. Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. Neurotoxicology. 2017;61:101&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">27377857</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H., Atsuta N., Nakamura R. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2014;15:129&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">25548957</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoi D., Atsuta N., Watanabe H. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis. Journal of Neurology. 2016;263:1129&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">27083563</ArticleId></ArticleIdList></Reference><Reference><Citation>Creemers H., Grupstra H., Nollet F., van den Berg L.H., Beelen A. Prognostic factors for the course of functional status of patients with ALS: a systematic review. J Neurol. 2015;262:1407&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">25385051</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B.R., Sawyer P., Roseman J.M., Allman RM. Marital status and health: exploring pre-widowhood. J Palliat Med. 2008;11:848&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6469521</ArticleId><ArticleId IdType="pubmed">18715177</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong S.W., Huisman M.H., Sutedja N.A. Smoking, alcohol consumption, and the risk of amyotrophic lateral sclerosis: a population-based study. Am J Epidemiol. 2012;176:233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">22791740</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F., Bellocco R., Hern&#xe1;n M.A., Ye W. Smoking, snuff dipping and the risk of amyotrophic lateral sclerosis - A prospective cohort study. Neuroepidemiology. 2006;27:217&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">17106211</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A., Logroscino G., Hern&#xe1;n MA. Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2010;81:1249&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pubmed">20639382</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Wei Q.Q., Chen Y. Clinical Staging of Amyotrophic Lateral Sclerosis in Chinese Patients. Front Neurol. 2018;9:442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6018204</ArticleId><ArticleId IdType="pubmed">29971035</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E., Siokas V., Sokratous M. Body mass index and survival from amyotrophic lateral sclerosis: A meta-analysis. Neurol Clin Pract. 2018;8:437&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6276330</ArticleId><ArticleId IdType="pubmed">30564498</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida F.E.O., Santana A.K.D., de Carvalho FO. Multidisciplinary care in Amyotrophic Lateral Sclerosis: a systematic review and meta-analysis. Neurological Sciences. 2021;42:911&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">33443670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D., Bejan-Angoulvant T., Patin F., Andres C.R., Vourc'h P., Corcia P., Blasco H. Plasma creatinine and amyotrophic lateral sclerosis prognosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:199&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">30961401</ArticleId></ArticleIdList></Reference><Reference><Citation>Radunovic A., Annane D., Rafiq M.K., Brassington R., Mustfa N. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6485636</ArticleId><ArticleId IdType="pubmed">28982219</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Corcia P., Fergani A. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., K&#xfc;hnlein P., Hendrich C., Kassubek J., Sperfeld A.D., Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. Journal of Neurology. 2011;258:613&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>